{"13":"Ягудина Р. ФАРМАКОЭКОНОМИКА. Том 4, №4, 2011,с. 3-7   ","14":"РКИ - рандомизированное контролируемое исследование 1. Ассоциация британской фармацевтической промышленности (Association of the British Pharmaceutical Industry, ABPI): The vision for real-world data – Harnessing the opportunities in the UK. Доступно по ссылке: http://www.abpi.org.uk/our-work/library/industry/Documents/Vision-for-Real-World-Data.pdf. Дата доступа: May 2017.  2. Cognizant 20-20 highlights – real-world evidence: A better life journey for pharmas, payers and patients.  Доступно по ссылке: http://www.cognizant.com/InsightsWhitepapers/real-world-evidence-a-better-life-journey-for-pharmas-payers-and-patients-codex1259.pdf. Дата доступа: May 2017.  3. Papp KA, et al. J Drugs Dermatol. 2015;14(7):706–14.  4. Lusignan S, et al. J Innov Health Inform. 2015;22(3):368–73.  Рисунок по материалам: Cognizant 20-20 highlights – real-world evidence: A better life journey for pharmas, payers and patients. Доступно по ссылке: http://www.cognizant.com/InsightsWhitepapers/real-world-evidence-a-better-life-journey-for-pharmas-payers-and-patients-codex1259.pdf. Дата доступа: Май 2017.  ","24":"Papp K. et al. Lancet. 2008:371:1675-84  ","31":"Инструкция по медицинскому примененияю препарата Стерала® (устекинумаб) ЛП-001104, ЛСР-006465/09 Электронный ресурс 25.08.2017 http://grls.rosminzdrav.ru/ \u0003Инструкция по медицинскому примерения препарата Секукинумаб ЛП-0037870, ЛП-003715. Электронный ресурс 25.08.2017 http://grls.rosminzdrav.ru/  \u0003Thaci D J AM Dermatol. 2015 Sep;73(3);400-9. doi: 10.1016/j.laad.2015.05.013. Epub 2015 Jun 17 Thaci D J AM Dermatol. 2015 Sep;73(3);400-9","39":"1. Kavanaugh A, et al. Arthritis Care Res. 2015;67(12):1739–49 2. Kavanaugh A et al. Ann Rheum Dis. 2016 Nov;75(11):1984-1988.  ","46":"Kavanaugh A et al. Ann Rheum Dis. 2016 Nov;75(11):1984-1988.. ","51":"Wendler J. et al, Ustekinumab for the treatment of psoriatic arthritis – Results of the first Interim analysis of the non-interventional study SUSTAIN, 44th of DGRh, 2016, Frankfurt, SP.36 Wendler J. et al.. THU0280, Annals of the Rheumatic Diseases 2018;77:358. http://dx.doi.org/10.1136/annrheumdis-2018-eular.6364  ","52":"Wendler J. et al, Ustekinumab for the treatment of psoriatic arthritis – Results of the first Interim analysis of the non-interventional study SUSTAIN, 44th of DGRh, 2016, Frankfurt, SP.36 Wendler J. et al.. THU0280, Annals of the Rheumatic Diseases 2018;77:358. http://dx.doi.org/10.1136/annrheumdis-2018-eular.6364  ","60":"Gisondi et Al. Br J Dermond. 2013 May: 168(5): 1124-7","64":"Kavanaugh A, et al. Arthritis Care Res. 2015;67(12):1739–49 Kavanaugh A et al. Ann Rheum Dis. 2016 Nov;75(11):1984-1988.  ","67":"Araujo et al. Semin Arthritis Rheumatism 2018; Epub 13JUN doi: 10.1016/j.semarthrit. 2018.05.011.","71":"Rich P et al. Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1. British Journal of Dermatology (2014) 170, pp398–407 ","76":"Egeberg A,Ottosen M, Gniadecki R et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis.Br J Dermatol. 2018 Feb;178(2):509-519 ","77":"Egeberg A,Ottosen M, Gniadecki R et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis.Br J Dermatol. 2018 Feb;178(2):509-519 "}